Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 26, 2021

Axonics acquires urethral bulking agent Bulkamid

Axonics Modulation Technologies has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used in the treatment of female stress urinary incontinence (SUI).

Axonics Modulation Technologies has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used in the treatment of female stress urinary incontinence (SUI).

The transaction includes a total consideration of $200m in cash and stock, along with a potential future milestone of $35m.

Bulkamid is a homogenous non-particulate hydrogel, which is injected into the urethral wall in a minimally invasive office or outpatient facility procedure for restoring the urethra’s natural closing pressure.

The company believes that Bulkamid addresses the defects of the existing particulate-based bulking agents while offering an alternative to patients who wish to avoid sling surgery and opt for a minimally invasive solution.

The hydrogel secured CE Mark approval in 2003 and the US Food and Drug Administration (FDA) approval last year.

Axonics CEO Raymond Cohen said: “This acquisition is highly synergistic, leverages our expansive commercial footprint and gives us the opportunity to expand our SNM business around the world.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Axonics will provide urogynecologists and urologists with a complete suite of clinically differentiated incontinence solutions for their patients, thereby enhancing Axonics’ value proposition to new and existing customers.

“Interestingly, in many cases, the patient seeking treatment presents with mixed incontinence, meaning with both SUI and urge urinary incontinence symptoms.”

The company noted that the cash for the acquisition is funded through a new $75m term loan from Silicon Valley Bank.

The payment of $35m is subject to the achievement of $50m in Bulkamid sales over any consecutive 12-month period prior to 31 December 2024.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU